Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed CD3+ T-cell lymphoma for which no standard curative therapy exists
• * Peripheral T-cell lymphoma
• * Recurrent and/or progressive disease after at least 1 prior therapy
• * Mycosis fungoides
• * Stage IB/IIA
• * Recurrent and/or progressive disease after at least 2 prior therapies
• * Stage IIB-IVB
• * Recurrent and/or progressive disease after at least 1 prior therapy
• * All other T-cell lymphomas
• * Recurrent and/or progressive disease after at least 1 prior therapy
• Evaluable disease
• * Any nodal site or mass lesion at least 1.5 cm in longest axis on physical exam or CT scan
• * Skin lesions at least 1 cm in longest axis for cutaneous lymphoma
• High numbers of circulating T-cells allowed
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Karnofsky 50-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 2,000/mm\^3\*
• Absolute neutrophil count at least 1,000/mm\^3\*
• Platelet count at least 75,000/mm\^3\* NOTE: \* Unless due to lymphoma
• Hepatic:
• Bilirubin no greater than 2.0 times normal\*
• AST/ALT no greater than 2.5 times upper limit of normal\*
• Hepatitis B and C negative NOTE: \* Unless due to lymphoma
• Renal:
• Not specified
• Cardiovascular:
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other:
• No other uncontrolled illness
• No ongoing or active infection
• No other active malignancies except basal cell skin cancer or carcinoma in situ of the cervix
• HIV-1 negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Biologic therapy:
• At least 60 days since prior humanized or chimeric antibody therapy
• Chemotherapy:
• At least 3 weeks since prior chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 3 weeks since prior radiotherapy
• Surgery:
• Not specified
• Other:
• At least 30 days since prior investigational drugs or therapies